Valuation: IRulya Therapeutics Inc.

Market Cap 33.8M 30.07M 27.84M 25.36M 47.78M 3.21B 48.67M 334M 131M 1.67B 127M 124M 5.34B P/E 2026 *
-3.61x
P/E 2027 * -4.69x
Enterprise Value -62M -55.17M -51.07M -46.52M -87.65M -5.89B -89.29M -614M -241M -3.07B -233M -228M -9.8B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day-3.61%
1 week+9.09%
Current month+3.29%
1 month+11.04%
3 months+72.39%
6 months+30.20%
Current year-95.22%
1 week 25.13
Extreme 25.13
34.93
1 month 25.13
Extreme 25.13
37
Current year 15.1
Extreme 15.1
744
1 year 15.1
Extreme 15.1
909.98
3 years 15.1
Extreme 15.1
909.98
5 years 15.1
Extreme 15.1
12,896
10 years 15.1
Extreme 15.1
24,396
Manager TitleAgeSince
Chief Executive Officer 50 07/10/2026
Director of Finance/CFO 52 07/10/2026
Chief Operating Officer - 07/10/2026
Director TitleAgeSince
Director/Board Member 50 17/05/2026
Director/Board Member - 07/10/2026
Director/Board Member 63 07/10/2026
Date Insider Type Main position Quantity % Market Cap. Importance
18/05/26 Free

Director

16,698,162 -
23/01/26 Free

Chief Financial Officer

365,000 0.6555%
23/01/26 Free

Chief Executive Officer

1,000,000 1.7959%
Change 5-day change 1-year change 3-year change Capi.($)
-3.61%+9.09%-91.91%-83.84% 33.8M
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%+3.12%+3.71%+53.50% 53.15B
+0.03%+7.21%+12.52%+44.46% 50.83B
-1.53%+3.10%+31.40%+33.88% 44.61B
-5.97%-5.40%+259.08%+494.98% 40.57B
-1.34%+5.41%+16.74%+106.42% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.76%-4.73%-15.94%-15.32% 22.66B
Average -1.84%+2.69%+31.38%+74.68% 37.98B
Weighted average by Cap. -2.32%+1.65%+46.49%+96.52%

Financials

2026 *2027 *
Net sales - -
Net income -69.81M -62.11M -57.5M -52.38M -98.69M -6.63B -101M -691M -271M -3.46B -262M -256M -11.03B -54.47M -48.46M -44.86M -40.87M -77M -5.17B -78.44M -539M -212M -2.7B -204M -200M -8.61B
Net Debt -95.8M -85.24M -78.9M -71.88M -135M -9.1B -138M -948M -372M -4.74B -359M -352M -15.14B -139M -124M -115M -105M -197M -13.24B -201M -1.38B -542M -6.9B -523M -512M -22.02B
Projected Income Statement - Annual - IRulya Therapeutics Inc.
Logo IRulya Therapeutics Inc.
IRulya Therapeutics, Inc., formerly Quince Therapeutics, Inc., is a clinical-stage biopharmaceutical company. It is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, and others.
Employees
38
Date Price Change Volume
16/10/26 US$32.03 -3.61% 11,521
15/10/26 US$33.23 +10.77% 8,981
14/10/26 US$30.00 +7.64% 26,944
13/10/26 US$27.87 -13.98% 84,308
12/10/26 US$32.40 +2.11% 76,907
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - IRulya Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
32.03USD
Average target price
75.00USD
Spread / Average Target
+134.16%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IRulya Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. IRLA Stock